GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Common Stock

Stoke Therapeutics (STU:0GT) Common Stock : €0.01 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Common Stock?

Stoke Therapeutics's quarterly common stock increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.01 Mil) but then stayed the same from Dec. 2023 (€0.01 Mil) to Mar. 2024 (€0.01 Mil).

Stoke Therapeutics's annual common stock stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.01 Mil).


Stoke Therapeutics Common Stock Historical Data

The historical data trend for Stoke Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Common Stock Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial - - - - 0.01

Stoke Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 0.01

Stoke Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Stoke Therapeutics (STU:0GT) Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Stoke Therapeutics (STU:0GT) Headlines

No Headlines